| | |
C.H. Unnikrishnan and Radhieka Pandeya 10:45 PM | July 29,2009
The country’s largest drug maker by market capitalization also incurred one-time severance costs from layoffs
|
|
Shereen Bhan / CNBC-TV18 10:34 PM | July 10,2009
Malvinder Singh, says that he is focusing on expanding his financial services firm Religare Enterprises Ltd and hospital chain Fortis Healthcare Ltd
|
|
Radhieka Pandeya 01:15 AM | June 04,2009
When it was founded in 1937, the then Ranbaxy and Co.’s first business was reselling drugs made by Japanese firm A Shiniogi. Seven decades later, the Singh family sold out to a Japanese firm
|
|
Lison Joseph 01:07 AM | June 01,2009
While Betapharm has increased DRL’s revenue, it has been a drag on the Indian drug maker’s profits due to a sharp decline in price in the German market
|
|
Radhieka Pandeya 10:26 PM | March 23,2009
This follows an action by the US Food and Drugs Administration, which on 25 February suspended review of all approval applications from the plant on charges of falsifying data and test results
|
|
Seema Singh 02:54 PM | February 18,2009
The new compound could lead to a single drug for TB, which is currently treated by a cocktail of four drugs, each inhibiting a single enzyme and attacking a single metabolic pathway of the bacterium that causes the disease
|
|
Kanoko Matsuyama / Bloomberg 11:20 PM | January 15,2009
The company was purchased by Daiichi Sankyo Co., Japan’s third largest drug maker, last year
|
|
Radhieka Pandeya 10:50 PM | December 19,2008
The firm has reduced the board’s size from 14 to 10 with six representatives of Daiichi Sankyo and three nominated by Singh
|
|
PTI 05:45 PM | December 03,2008
The company has also received the import permission for marketing the USFDA approved drug ‘GLIADEL Wafer’in India
|
|
AP 01:22 PM | November 07,2008
Daiichi Sankyo Co. agreed to pay more than $4 billion for a controlling stake in Ranbaxy in June
|
|
Saikat Chatterjee and Cherian Thomas / Bloomberg 12:31 AM | October 04,2008
Daiichi Sankyo, which aims to complete the transaction by March, still needs approval of the Reserve Bank of India
|
|
Saikat Chatterjee / Bloomberg 12:51 AM | October 03,2008
The US is probing whether the firm destroyed reports it was required to keep, falsified data and failed to meet quality control specifications in manufacturing the generic drugs it sells
|
|
Mark To Market | Manas Chakravarty 12:28 AM | September 30,2008
The Indian market has now given up all the gains it had made as a result of the falling price of crude
|
|
Justin Blum / Bloomberg 12:57 AM | September 26,2008
FDA had said on 16 September that more than 30 generic drugs made by Ranbaxy, India’s largest drug maker, would be blocked at US borders
|
|
08:01 AM | September 22,2008
The central bank suggested making it mandatory for banks to seek its approval before launching mobile banking services
|
|